Omnicell (OMCL) 10-Q 4 May 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	Apr. 26, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	OMNICELL, Inc
Entity Central Index Key	926,326
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		38,877,926
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 43,773	$ 32,424
Accounts receivable and unbilled, net of allowances of $5,203 and $5,738, respectively	190,678	190,046
Inventories	101,868	96,137
Prepaid expenses	21,161	20,392
Other current assets	14,751	13,273
Total current assets	372,231	352,272
Property and equipment, net	48,290	42,595
Long-term investment in sales-type leases, net	16,444	15,435
Goodwill	338,948	337,751
Intangible assets, net	162,458	168,107
Long-term deferred tax assets	9,456	9,454
Prepaid commissions	39,636	41,432
Other long-term assets	53,492	49,316
Total assets	1,040,955	1,016,362
Current liabilities:
Accounts payable	37,859	48,290
Accrued compensation	29,632	27,241
Accrued liabilities	40,519	35,693
Long-term debt, current portion, net	17,708	15,208
Short-term deferred revenue	95,709	78,774
Total current liabilities	221,427	205,206
Long-term deferred revenue	8,806	10,623
Long-term deferred tax liabilities	36,320	41,446
Other long-term liabilities	9,410	9,829
Long-term debt, net	190,490	194,917
Total liabilities	466,453	462,021
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued	0	0
Common stock, $0.001 par value, 100,000 shares authorized; 48,005 and 47,577 shares issued; 38,860 and 38,432 shares outstanding, respectively	48	48
Treasury stock at cost, 9,145 shares outstanding	(185,074)	(185,074)
Additional paid-in capital	600,525	585,755
Retained earnings	162,442	159,725
Accumulated other comprehensive loss	(3,439)	(6,113)
Total stockholders’ equity	574,502	554,341
Total liabilities and stockholders’ equity	$ 1,040,955	$ 1,016,362

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Allowances	$ 5,203	$ 5,738
Preferred stock, shares, issued (in shares)	0	0
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares, authorized (in shares)	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares, authorized (in shares)	100,000,000	100,000,000
Common Stock, shares, issued (in shares)	48,005,000	47,577,000
Common stock, shares, outstanding (in shares)	38,860,000	38,432,000
Treasury stock, shares (in shares)	9,145,000	9,145,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenues:
Product	$ 130,104	$ 98,702
Services and other revenues	52,515	49,851
Total revenues	182,619	148,553
Cost of revenues:
Cost of product revenues	75,417	63,588
Cost of services and other revenues	24,747	22,774
Total cost of revenues	100,164	86,362
Gross profit	82,455	62,191
Operating expenses:
Research and development	16,537	16,803
Selling, general and administrative	65,285	61,940
Total operating expenses	81,822	78,743
Income (loss) from operations	633	(16,552)
Interest and other income (expense), net	(2,729)	(2,456)
Loss before provision for income taxes	(2,096)	(19,008)
Benefit from income taxes	(4,816)	(8,673)
Net income (loss)	$ 2,720	$ (10,335)
Net income (loss) per share:
Net income (loss) per share - basic (in dollars per share)	$ 0.07	$ (0.28)
Net income (loss) per share - diluted (in dollars per share)	$ 0.07	$ (0.28)
Weighted-average shares outstanding:
Weighted-average shares outstanding — basic (in shares)	38,635	36,840
Weighted-average shares outstanding — diluted (in shares)	39,691	36,840

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 2,720	$ (10,335)
Other comprehensive income, net of reclassification adjustments:
Unrealized gains on interest rate swap contracts, net of tax	202	182
Foreign currency translation adjustments	2,472	923
Other comprehensive income	2,674	1,105
Comprehensive income (loss)	$ 5,394	$ (9,230)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating Activities
Net income (loss)	$ 2,720	$ (10,335)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	12,310	12,448
Share-based compensation expense	6,528	5,511
Income tax benefits from employee stock plans	0	11
Deferred income taxes	(5,128)	(8,826)
Amortization of debt financing fees	573	397
Changes in operating assets and liabilities, net of business acquisitions:
Accounts receivable and unbilled	(632)	21,642
Inventories	(6,881)	(6,933)
Prepaid expenses	(769)	79
Other current assets	(997)	374
Investment in sales-type leases	(1,491)	1,120
Prepaid commissions	1,796	208
Other long-term assets	(1,673)	(9,435)
Accounts payable	(9,416)	11,104
Accrued compensation	2,391	1,955
Accrued liabilities	4,276	(115)
Deferred revenue	15,118	8,471
Other long-term liabilities	131	506
Net cash provided by operating activities	18,856	28,182
Investing Activities
Purchases of intangible assets, intellectual property and patents	0	(160)
Software development for external use	(5,272)	(4,225)
Purchases of property and equipment	(9,268)	(2,452)
Net cash used in investing activities	(14,540)	(6,837)
Financing Activities
Repayment of debt and revolving credit facility	(2,500)	(40,000)
Proceeds from stock issuances under stock-based compensation plans	9,541	10,916
Employees' taxes paid related to restricted stock units	(1,300)	(1,052)
Net cash provided by (used in) financing activities	5,741	(30,136)
Effect of exchange rate changes on cash and cash equivalents	1,292	651
Net increase (decrease) in cash and cash equivalents	11,349	(8,140)
Cash and cash equivalents at beginning of period	32,424	54,488
Cash and cash equivalents at end of period	43,773	46,348
Supplemental disclosure of non-cash activities
Unpaid purchases of property and equipment	676	865
Effect of adoption of ASU No. 2016-09, Compensation - Stock Compensation (Topic 718)	$ 0	$ 1,582

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	Organization and Summary of Significant Accounting Policies Business Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. The Company's major products are automated medication, supply control systems and medication adherence solutions which are sold in its principal market, which is the healthcare industry. The Company's market is primarily located in the United States and Europe. "Omnicell" or the "Company" collectively refer to Omnicell, Inc. and its subsidiaries. Basis of presentation The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of March 31, 2018 and December 31, 2017 , the results of its operations, comprehensive income (loss) and cash flows for the three months ended March 31, 2018 and March 31, 2017 . Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in the Company's annual report on Form 10-K for the year ended December 31, 2017 filed with the SEC on February 27, 2018, except as discussed in the "Revenue recognition" below. The Company's results of operations, comprehensive income (loss) and cash flows for the three months ended March 31, 2018 are not necessarily indicative of results that may be expected for the year ending December 31, 2018 , or for any future period. Certain prior year amounts have been adjusted to conform with the adoption of ASC 606, Revenue from Contracts with Customers ("ASC 606"), which became effective for the Company beginning on January 1, 2018. Refer to "Recently adopted authoritative guidance" for the effects of adoption of ASC 606 and the section below for the updated revenue recognition policy. Principles of consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Revenue recognition The Company earns revenues from sales of its medication and medical and surgical supply automation systems along with consumables and related services, which are sold in the healthcare industry, our principal market. The transaction price of each contract with a customer is allocated to identified performance obligations based on the relative fair value of each obligation. The Company's customer arrangements typically include one or more of the following performance obligations: Products. Software-enabled equipment that manages and regulates the storage and dispensing of pharmaceuticals, consumable blister cards and packaging equipment and other medical supplies. Software. Additional software applications that enable incremental functionality of its equipment. Installation. Installation of equipment as integrated systems at customers' sites. Post-installation technical support. Phone support, on-site service, parts and access to unspecified software updates and enhancements, if and when available. Professional services. Other customer services, such as training and consulting. Prior to recognizing revenue, the Company identifies the contract, performance obligations, and transaction price, and allocates the transaction price to the performance obligations. All identified contracts meet the following required criteria: Parties to the contract have approved the contract (in writing, orally, or in accordance with other customary business practices) and are committed to perform their respective obligations. A majority of the Company’s contracts are evidenced by a non-cancelable written agreement. Contracts for consumable products are generally evidenced by an order placed via phone or a manual purchase order. Entity can identify each party’s rights regarding the goods or services to be transferred . Contract terms are documented within the written agreements. Where a written contract does not exist, such as for consumable products, the rights of each party are understood as following our standard business process and terms. The entity can identify the payment terms for the goods or services to be transferred . Payment terms are documented within the agreement and are generally net 30 days from shipment of tangible product or services performed. Where a written contract does not exist, the Company’s standard payment terms are net 30 day terms. The contract has commercial substance (that is the risk, timing, or amount of the entity’s future cash flows is expected to change as a result of the contract.) The Company's agreements are an exchange of cash for a combination of products and services which result in changes in the amount of the Company’s future cash flows. It is probable the entity will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer . The Company performs a credit check for all significant customers or transactions and where collectability is not probable, payment in full or a substantial down payment is typically required to help assure the full agreed upon contract price will be collected. The Company often enters into change orders which modify the product to be received by the customer pursuant to certain contracts. Changes to any contract are accounted for as a modification of the existing contract to the extent the goods and services to be delivered as part of the contract are generally consistent with the nature and type of those to be provided under the terms of the original contract. Examples of such change orders include the addition or removal of units of equipment or changes to the configuration of the equipment where the overall nature of the contract remains intact. The Company’s change orders generally result in the change being accounted for as modifications of existing contracts given the nature of the impacted orders. Distinct goods or services are identified as performance obligations. A series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer are considered a single performance obligation. Where a good or service is determined not to be distinct, the Company combines the good or service with other promised goods or services until a bundle of goods or services that is distinct is identified. To identify its performance obligations, the Company considers all of the products or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. When performance obligations are included in separate contracts, the Company considers an entire customer arrangement to determine if separate contracts should be considered combined for the purposes of revenue recognition. Most of the Company’s sales, other than renewals of support and maintenance, contain multiple performance obligations, with a combination of hardware systems, consumables and software products, support and maintenance, and professional services. The transaction price of a contract is determined based on the fixed consideration, net of an estimate for variable consideration such as various discounts or rebates provided to customers. As a result of the Company’s commercial selling practices, contract prices are generally fixed with minimal, if any, variable consideration. The transaction price is allocated to separate performance obligations proportionally based on the standalone selling price of each performance obligation. Standalone selling price is best evidenced by the price the Company charges for the good or service when selling it separately in similar circumstances to similar customers. Other than for the renewal of annual support services contracts, the Company’s products and services are not generally sold separately. The Company uses an expected cost plus a margin approach to identify the standalone selling price of goods where separate sales transactions do not exist. For software and services which do not have a specific identifiable product cost, the Company uses a discounted from the list price amount as a best estimated selling price. The Company recognizes revenue when the performance obligation has been satisfied by transferring a promised good or service to a customer. The good or service is transferred when or as the customer obtains control of the good or service. Determining when control transfers requires management to make judgments that affect the timing of revenue recognized. Generally, for products requiring a complex implementation, control passes when the product is installed and ready for use. For all other products, control generally passes when product has been shipped and title has passed. For maintenance contracts and certain other services provided on a subscription basis, control passes to the customer over time, generally ratably over the service term as the Company provides a stand-ready service to service the customer’s equipment. Time and material services transfer control to the customer at the time the services are provided. The portion of the transaction price allocated to the Company’s unsatisfied performance obligation at March 31, 2018 and December 31, 2017 was $104.5 million and $89.4 million , respectively, of which $95.7 million and $78.8 million , respectively, was expected to be completed within one year. Remaining performance obligations primarily relate to maintenance contracts and are recognized ratably over the remaining term of the contract, generally not more than five years. Revenues, contract assets and contract liabilities are recorded net of associated taxes. The payment terms associated with the Company’s contracts vary, however, payment terms for product revenue are generally based on milestones tied to contract signing, shipment of products and/or customer acceptance. Payment terms associated with the service portion of agreements are generally periodic and can be billed on a monthly, quarterly or annual basis. In certain circumstances multiple years are billed at one time. The portion of these contract liabilities not expected to be recognized as revenue within twelve months of the balance sheet date are considered long term. In the normal course of business, the Company typically does not accept product returns unless the item is defective as manufactured or the configuration of the product is incorrect. The Company establishes provisions for estimated returns based on historical product returns. The allowance for sales returns is not material to the Condensed Consolidated Financial Statements for any periods presented. A portion of the Company's sales are made through multi-year lease agreements. Under sales-type leases, the Company recognizes revenue for its hardware and software products net of lease execution costs, such as post-installation product maintenance and technical support, at the net present value of the lease payment stream once its installation obligations have been met. The Company optimizes cash flows by selling a majority of its non-U.S. government leases to third-party leasing finance companies on a non-recourse basis. The Company has no obligation to the leasing company once the lease has been sold. Some of the Company's sales-type leases, mostly those relating to U.S. government hospitals which comprise approximately 40% of the lease receivable balance, are retained in-house. Revenue from sales-type leases of $9.8 million and $3.2 million for the three months ended March 31, 2018 and 2017, respectively, is included in product revenue in the Condensed Consolidated Statements of Operations. Interest income in these leases is recognized in product revenue using the effective interest method. A portion of the Company’s sales are made to customers who are members of Group Purchasing Organizations ("GPOs"). GPOs are often owned fully or in part by the Company’s customers and the Company pays fees to the GPO on completed contracts. The Company considers these fees consideration paid to customers and records them as reductions to revenue. Fees to GPOs were $1.9 million and $2.1 million for the quarters ended March 31, 2018 and 2017, respectively. Contract assets and contract liabilities A contract asset is a right to consideration in exchange for goods or services that the Company has transferred to a customer when that right is conditional and is not just subject to the passage of time. A receivable will be recorded on the balance sheet when the Company has unconditional rights to consideration. A contract liability is an obligation to transfer goods or services for which the Company has received consideration, or for which an amount of consideration is due from the customer. Contract liabilities include customer deposits under non-cancelable contracts and current and non-current deferred revenue balances. The Company’s contract balances are reported in a net contract asset or liability position on a contract-by-contract basis at the end of each reporting period. The following table reflects the Company’s contract assets and contract liabilities: March 31, December 31, (In thousands) Short-term unbilled receivable - included in accounts receivable and unbilled $ 4,859 $ 4,590 Long-term unbilled receivable - included in other long-term assets 10,877 9,475 Total contract assets $ 15,736 $ 14,065 Short-term deferred revenue $ 95,709 $ 78,774 Long-term deferred revenue 8,806 10,623 Total contract liabilities $ 104,515 $ 89,397 Significant changes in the contract assets and the contract liabilities balances during the period are the result of the issuance of invoices and recognition of deferred revenue in the normal course of business. Unbilled contract assets which were invoiced during the three months ended March 31, 2018 as a result of the right to invoice for the transaction consideration becoming unconditional were not material. The contract modifications entered into during the three months ended March 31, 2018, did not have a significant impact on the Company’s contract assets or deferred revenues. During the three months ended March 31, 2018, the Company recognized revenue of $46.6 million that was included in the corresponding deferred revenue balance as of December 31, 2017. Contract costs The Company has determined that the incentive portions of its sales commission plans require capitalization since these payments are directly related to sales achieved during a time period. These commissions are earned on the basis of the total purchase order value of new product bookings. Since there are not commensurate commissions earned on renewal of the service bookings, the Company concluded that the capitalized asset is related to services provided under both the initial contract and renewal periods. The Company applies a practical expedient to account for the incremental costs of obtaining a contract to a portfolio of contracts with similar characteristics as the Company expects the effect on the financial statements of applying the practical expedient would not differ materially from applying the accounting guidance to the individual contracts within the portfolio. A pool of contracts is defined as all contracts booked in a particular quarter. The amortization for the capitalized asset is an estimate of the pool’s original contract term, generally one to five years, plus an estimate of future customer renewal periods resulting in a total amortization period of ten years. Costs to obtain a contract are allocated amongst performance obligations and recognized as sales and marketing expense consistent with the pattern of revenue recognition. Capitalized costs are periodically reviewed for impairment. A portion of the pool’s capitalized asset is recorded as an expense after two quarters, which represents the estimated period during which the product revenue associated with the contract is recorded. The remaining contract cost is recorded as expense ratably over the ten year estimated initial and renewal service periods. During the three months ended March 31, 2018 and March 31, 2017, the Company recognized contract cost expense of $5.6 million and $4.1 million , respectively. The portion of commission expenses paid as of the balance sheet date to be recognized in future periods is recorded in long term prepaid commissions expense on the Condensed Consolidated Balance Sheets. There was no impairment loss in relation to the costs capitalized during the three months ended March 31, 2018. Use of estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company's Condensed Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company's critical accounting policies are those that affect its financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, accounts receivable and notes receivable from investment in sales-type leases, inventory valuation, capitalized software development costs, valuation and impairment of goodwill, purchased intangibles and long-lived assets, fair value of assets acquired and liabilities assumed in business combination, share-based compensation, and accounting for income taxes. Segment reporting The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company's segments using information about its revenues, gross profit, and income from operations. Such evaluation excludes general corporate-level costs that are not specific to either of the reportable segments and are managed separately at the corporate level. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain other administrative expenses. See Note 14, Segment and Geographical Information, for additional information on segment reporting. Recently adopted authoritative guidance In May 2014, the Financial Accounting Standards Board ("FASB") issued ASC 606, Revenue from Contracts with Customer s, a new standard related to revenue recognition. Under the new standard, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective method). We adopted the standard using the full retrospective method effective beginning January 1, 2018. Under the ASC 606 guidance, fees paid to GPOs are now presented as a reduction of Product Revenue, whereas these fees were considered a part of Selling, General and Administrative costs under the previous guidance. The majority of the incremental costs incurred to obtain a contract, primarily commission expense, are recognized during the first year with the balance recognized ratably over a period of ten years. Additionally, revenue on term software licenses is recognized upon installation of the license rather than ratably over the life of the term license. Finally, the Company no longer defers the contingent revenue in transactions where the amount charged to the customer for a particular performance obligation is less than the allocation of standalone selling price. Adoption of the standard related to revenue recognition impacted our reported results for the three months period, as follows: March 31, 2017 As reported Adjustment As adjusted (In thousands) Revenue Automation and Analytics $ 124,171 $ (2,001 ) $ 122,170 Medication Adherence 26,383 — 26,383 Gross profit Automation and Analytics 55,410 (2,001 ) 53,409 Medication Adherence 8,782 — 8,782 Selling, general and administrative expenses 64,625 (2,685 ) 61,940 Provision for income taxes (8,938 ) 265 (8,673 ) Net income $ (10,754 ) $ 419 $ (10,335 ) Earnings per share $ (0.29 ) $ 0.01 $ (0.28 ) December 31, 2017 As reported Adjustment As adjusted (In thousands) Accounts receivable and unbilled, net $ 189,227 $ 819 $ 190,046 Prepaid expenses 36,060 (15,668 ) 20,392 Prepaid commissions — 41,432 41,432 Other long-term assets 39,841 9,475 49,316 Deferred revenue, net 86,104 (7,330 ) 78,774 Long-term, deferred revenue 17,244 (6,621 ) 10,623 Long-term, deferred tax liabilities 28,579 12,867 41,446 Stockholders' equity 517,199 37,142 554,341 Recently issued authoritative guidance In February 2018, the FASB issued ASU 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which permits the reclassification of the income tax effects of the Tax Cuts and Jobs Act of 2017 on items within accumulated other comprehensive income to retained earnings. These amounts are commonly referred to as “stranded tax effects”. ASU 2018-02 will be effective for the Company beginning January 1, 2019. The Company is currently in the process of evaluating the impact of adoption on the consolidated financial statements. There was no other recently issued and effective authoritative guidance that is expected to have a material impact on the Company's Condensed Consolidated Financial Statements through the reporting date.

Business Acquisitions

Business Acquisitions	3 Months Ended
	Mar. 31, 2018
Business Combinations [Abstract]
Business Acquisitions	Business Acquisitions 2017 Acquisitions On April 12, 2017, the Company completed the acquisition of all of the membership interest of Dixie Drawl, LLC d/b/a InPharmics ("InPharmics"). InPharmics is a technology and services company that provides advanced pharmacy informatics solutions to hospital pharmacies. The total consideration for the transaction was $5.0 million , net of cash acquired of $0.3 million , and includes $0.5 million holdback for potential settlement of performance obligations. At March 31, 2018, this amount has been presented as a short-term liability. The Company accounted for the acquisition of InPharmics in accordance with the authoritative guidance on business combinations; therefore, the tangible and intangible assets acquired and liabilities assumed were recorded at fair value on the acquisition date. The purchase price was preliminary allocated to intangible assets in the amount of $1.9 million , which included developed technology and customer contracts, with the remainder allocated to goodwill. The results of the InPharmics' operations have been included in our consolidated results of operations, and presented as part of the Automation and Analytics segment.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	3 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Net Income (Loss) Per Share Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares outstanding during the period, less shares repurchased. In periods of net loss, all potential common shares are anti-dilutive, so diluted net loss per share equals the basic net loss per share. In periods of net income, diluted net income per share is computed by dividing net income for the period by the basic weighted-average number of shares plus any dilutive potential common stock outstanding during the period. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards and restricted stock units computed using the treasury stock method. Any anti-dilutive weighted-average dilutive shares related to stock award plans are excluded from the computation of the diluted net income per share. The basic and diluted net income (loss) per share calculation for the three months ended March 31, 2018 and 2017 was as follows: Three months ended March 31, 2018 2017 (In thousands, except per share data) Net income (loss) $ 2,720 $ (10,335 ) Weighted-average shares outstanding — basic 38,635 36,840 Effect of dilutive securities from stock award plans 1,056 — Weighted-average shares outstanding — diluted $ 39,691 $ 36,840 Net income (loss) per share - basic $ 0.07 $ (0.28 ) Net income (loss) per share - diluted $ 0.07 $ (0.28 ) Anti-dilutive weighted-average shares related to stock award plans 1,113 4,236

Cash and Cash Equivalents and F

Cash and Cash Equivalents and Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents and Fair Value of Financial Instruments	Cash and Cash Equivalents and Fair Value of Financial Instruments Cash and cash equivalents of $43.8 million and $32.4 million as of March 31, 2018 and December 31, 2017 , respectively, consisted of demand deposits only. Interest Rate Swap Contracts The Company uses interest rate swap agreements to protect the Company against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of its outstanding debt. The Company's interest rate swaps, which are designated as cash flow hedges, involve the receipt of variable amounts from counterparties in exchange for the Company making fixed-rate payments over the life of the agreements. The Company does not hold or issue any derivative financial instruments for speculative trading purposes. During 2016, the Company entered into an interest rate swap agreement with a combined notional amount of $100.0 million with one counter-party that became effective on June 30, 2016 and is maturing on April 30, 2019. The swap agreement requires the Company to pay a fixed rate of 0.8% and provides that the Company will receive a variable rate based on the one month LIBOR rate subject to a LIBOR floor of 0.0% . Amounts payable by or due to the Company will be net settled with the respective counter-party on the last business day of each month, commencing July 31, 2016. The fair value of the interest rate swap agreements at March 31, 2018 and December 31, 2017 was $1.5 million and $1.4 million , respectively. There were no amounts reclassified into current earnings due to ineffectiveness during the periods presented. Fair value hierarchy The Company measures its financial instruments at fair value. The Company’s cash equivalents are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company's interest rate swap contracts and foreign currency contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. The following table represents the fair value hierarchy of the Company’s financial assets and financial liabilities measured at fair value as of March 31, 2018 : Level 1 Level 2 Level 3 Total (In thousands) Interest rate swap contracts $ — $ 1,464 $ — $ 1,464 Total financial assets $ — $ 1,464 $ — $ 1,464 There were no transfers between fair value measurement levels during the three months ended March 31, 2018 and March 31, 2017 . The following table represents the fair value hierarchy of the Company’s financial assets and financial liabilities measured at fair value as of December 31, 2017 : Level 1 Level 2 Level 3 Total (In thousands) Interest rate swap contracts $ — $ 1,378 $ — $ 1,378 Total financial assets $ — $ 1,378 $ — $ 1,378 Net investment in sales-type leases. The carrying amount of the Company's sales-type lease receivables is a reasonable estimate of fair value, as the unearned interest income is immaterial.

Balance Sheet Components

Balance Sheet Components	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Balance Sheet Components Balance sheet details as of March 31, 2018 and December 31, 2017 are presented in the tables below: March 31, December 31, (In thousands) Inventories: Raw materials $ 25,103 $ 22,750 Work in process 9,959 9,818 Finished goods and service parts 66,806 63,569 Total inventories $ 101,868 $ 96,137 Property and equipment: Equipment $ 72,122 $ 69,550 Furniture and fixtures 6,750 6,534 Leasehold improvements 14,540 10,976 Software 38,840 37,168 Construction in progress 11,334 9,813 Property and equipment, gross 143,586 134,041 Accumulated depreciation and amortization (95,296 ) (91,446 ) Total property and equipment, net $ 48,290 $ 42,595 Other long term assets: Capitalized software, net $ 41,146 $ 38,599 Unbilled receivable 10,877 9,475 Other assets 1,469 1,242 Total other long term assets, net $ 53,492 $ 49,316 March 31, December 31, Accrued liabilities: Advance payments from customers $ 6,879 $ 7,779 Rebates and lease buyouts 5,342 5,428 Group purchasing organization fees 3,439 3,449 Taxes payable 12,135 9,183 Other accrued liabilities 12,724 9,854 Total accrued liabilities $ 40,519 $ 35,693 The following table summarizes the changes in accumulated balances of other comprehensive income (loss) for the three months ended March 31, 2018 and 2017 : Three months ended March 31, 2018 2017 Foreign currency translation adjustments Unrealized gain (loss) on interest rate swap hedges Total Foreign currency translation adjustments Unrealized gain (loss) on interest rate swap hedges Total (In thousands) Beginning balance $ (6,954 ) $ 841 $ (6,113 ) $ (10,764 ) $ 1,245 $ (9,519 ) Other comprehensive income (loss) before reclassifications 2,472 401 2,873 923 176 1,099 Amounts reclassified from other comprehensive income (loss), net of tax (199 ) (199 ) — 6 6 Net current-period other comprehensive income (loss), net of tax 2,472 202 2,674 923 182 1,105 Ending balance $ (4,482 ) $ 1,043 $ (3,439 ) $ (9,841 ) $ 1,427 $ (8,414 )

Net Investment in Sales-Type Le

Net Investment in Sales-Type Leases	3 Months Ended
	Mar. 31, 2018
Leases [Abstract]
Net Investment in Sales-Type Leases	Net Investment in Sales-Type Leases On a recurring basis, we enter into sales-type lease transactions with the majority varying in length from one to five years. The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at March 31, 2018 and December 31, 2017 : March 31, December 31, (In thousands) Net minimum lease payments to be received $ 26,789 $ 25,899 Less: Unearned interest income portion (2,056 ) (1,695 ) Net investment in sales-type leases 24,733 24,204 Less: Short-term portion (1) (8,289 ) (8,769 ) Long-term net investment in sales-type leases $ 16,444 $ 15,435 (1) The short-term portion of the net investments in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets. The Company evaluates its sales-type leases individually and collectively for impairment. The allowance for credit losses were $0.2 million as of March 31, 2018 and December 31, 2017 . At March 31, 2018 , the future minimum lease payments under sales-type leases were as follows: March 31, (In thousands) Remaining nine months of 2018 $ 5,293 2019 7,872 2020 1,938 2021 5,203 2022 3,386 Thereafter 3,097 Total $ 26,789

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The following table represents changes in the carrying amount of goodwill: Automation and Analytics Medication Adherence Total (In thousands) Net balance as of December 31, 2017 $ 220,851 $ 116,900 $ 337,751 Foreign currency exchange rate fluctuations 831 366 1,197 Net balance as of March 31, 2018 $ 221,682 $ 117,266 $ 338,948 Intangible assets, net The carrying amounts of intangible assets as of March 31, 2018 and December 31, 2017 were as follows: March 31, 2018 Gross carrying amount Accumulated amortization Foreign currency exchange rate fluctuations Net carrying amount Useful life (years) (In thousands, except for years) Customer relationships $ 133,950 $ (36,356 ) $ 314 $ 97,908 1 - 30 Acquired technology 74,371 (23,359 ) 203 51,215 3 - 20 Backlog 21,712 (18,424 ) — 3,288 1 - 4 Trade names 8,662 (4,861 ) 38 3,839 1 - 12 Patents 3,236 (1,390 ) 12 1,858 2 - 20 Non-compete agreements 1,900 (1,450 ) — 450 3 In-process technology 3,900 — — 3,900 — Total intangibles assets, net $ 247,731 $ (85,840 ) $ 567 $ 162,458 December 31, 2017 Gross carrying amount Accumulated amortization Foreign currency exchange rate fluctuations Net carrying amount Useful life (years) (In thousands, except for years) Customer relationships $ 133,913 $ (33,526 ) $ 65 $ 100,452 1 - 30 Acquired technology 74,593 (21,523 ) 34 53,104 3 - 20 Backlog 21,712 (17,544 ) — 4,168 1 - 5 Trade names 8,716 (4,719 ) 6 4,003 1 - 12 Patents 3,296 (1,418 ) 2 1,880 2 - 20 Non-compete agreements 1,900 (1,300 ) — 600 3 In-process technology 3,900 — — 3,900 — Total intangibles assets, net $ 248,030 $ (80,030 ) $ 107 $ 168,107 Amortization expense of intangible assets was $6.0 million and $6.5 million for the three months ended March 31, 2018 and 2017 , respectively. The estimated future amortization expenses for amortizable intangible assets are as follows: March 31, 2018 (In thousands) Remaining nine months of 2018 $ 17,463 2019 18,036 2020 16,832 2021 15,378 2022 14,009 Thereafter (excluding in-process technology) 76,840 Total $ 158,558

Debt

Debt	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Debt	Debt On January 5, 2016 , the Company entered into a $400 million senior secured credit facility pursuant to a credit agreement, by and among the Company, the lenders from time to time party thereto, Wells Fargo Securities, LLC, as Sole Lead Arranger and Wells Fargo Bank, National Association, as administrative agent (the “Credit Agreement”). The Credit Agreement provides for (a) a five -year revolving credit facility of $200 million , which was subsequently increased pursuant to the amendment discussed below (the “Revolving Credit Facility”) and (b) a five -year $200 million term loan facility (the “Term Loan Facility” and together with the Revolving Credit Facility, the “Facilities”). In addition, the Credit Agreement includes a letter of credit sub-limit of up to $10 million and a swing line loan sub-limit of up to $10 million . The Credit Agreement expires on January 5, 2021, upon which date all remaining outstanding borrowings are due and payable. Loans under the Facilities bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR Rate, plus an applicable margin ranging from 1.50% to 2.25% per annum based on the Company’s consolidated total net leverage ratio (as defined in the Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50% , and (iii) LIBOR for an interest period of one month, plus an applicable margin ranging from 0.50% to 1.25% per annum based on the Company’s consolidated total net leverage ratio (as defined in the 2016 Credit Agreement). Undrawn commitments under the Revolving Credit Facility will be subject to a commitment fee ranging from 0.20% to 0.35% per annum based on the Company’s consolidated total net leverage ratio on the average daily unused portion of the Revolving Credit Facility. A letter of credit participation fee ranging from 1.50% to 2.25% per annum based on the Company’s consolidated total net leverage ratio will accrue on the average daily amount of letter of credit exposure. The Company is permitted to make voluntary prepayments at any time without payment of a premium or penalty, except for any amounts relating to the LIBOR breakage indemnity described in the Credit Agreement. The Company is required to make mandatory prepayments under the Term Loan Facility with (a) net cash proceeds from any issuances of debt (other than certain permitted debt) and (b) net cash proceeds from certain asset dispositions (other than certain asset dispositions) and insurance and condemnation events (subject to reinvestment rights and certain other exceptions). Loans under the Term Loan Facility will amortize in quarterly installments, equal to 5% per annum of the original principal amount thereof during the first two years, which shall increase to 10% per annum during the third and fourth years, and 15% per annum during the fifth year, with the remaining balance payable on January 5, 2021. The Company is required to make mandatory prepayments under the Revolving Credit Facility if at any time the aggregate outstanding principal amount of loans together with the total amount of outstanding letters of credit exceeds the aggregate commitments, with such mandatory prepayment to be equal to the amount of such excess. The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends and other distributions. The Credit Agreement contains financial covenants that require the Company and its subsidiaries to not exceed a maximum consolidated total leverage ratio and maintain a minimum fixed charge coverage ratio. The Company’s obligations under the Credit Agreement and any swap obligations and banking services obligations owing to a lender (or an affiliate of a lender) are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and the subsidiary guarantors’ assets. In connection with entering into the Credit Agreement, and as a condition precedent to borrowing loans thereunder, the Company and certain of the Company’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a collateral agreement and subsidiary guaranty agreement. On April 11, 2017, the parties entered into the First Amendment to Credit Agreement and Collateral Agreement (the "Amended Credit Agreement"). Under this amendment, (i) the maximum capital expenditures limit in any fiscal year for property, plant and equipment and software development increased from $35.0 million to $45.0 million , and (ii) the maximum limit for non-permitted investments increased from $10.0 million to $20.0 million . On December 26, 2017, the parties entered into another amendment (the "Amendment") to the Amended Credit Agreement. Pursuant to the Amendment, the Revolving Credit Facility provided for under the Amended Credit Agreement, was increased from $200.0 million to $315.0 million and certain other modifications to the Amended Credit Agreement were made, including amendments to certain negative covenants. In connection with these Facilities, the Company incurred $10.1 million of debt issuance costs. The debt issuance costs were capitalized and presented as a direct deduction from the carrying amount of that debt liability in accordance with the accounting guidance. The debt issuance costs are being amortized to interest expense using the straight line method from issuance date through 2021. Interest expense (exclusive of fees and issuance cost amortization) was approximately $1.9 million and $1.5 million for the three months ended March 31, 2018 and 2017 , respectively. Amortization expense related to fees and issuance cost was approximately $0.6 million and $0.4 million for the three months ended March 31, 2018 and 2017 , respectively. The Company was in compliance with all covenants as of March 31, 2018 and December 31, 2017 . As of March 31, 2018 the Company has repaid $139.5 million borrowed under these Facilities, which includes $2.5 million repaid during the three months ended March 31, 2018 . The components of the Company’s debt obligations as of March 31, 2018 and December 31, 2017 are as follows: December 31, 2017 Borrowings Repayment / Amortization March 31, 2018 (In thousands) Term loan facility $ 182,500 $ — $ (2,500 ) $ 180,000 Revolving credit facility 34,500 — — 34,500 Total debt under the facilities 217,000 — (2,500 ) 214,500 Less: Deferred issuance cost (6,875 ) — 573 (6,302 ) Total Debt, net of deferred issuance cost $ 210,125 $ — $ (1,927 ) $ 208,198 Long term debt, current portion, net of deferred issuance cost 15,208 17,708 Long term debt, net of deferred issuance cost $ 194,917 $ 190,490 As of March 31, 2018 , the carrying amount of debt of $214.5 million approximates the comparable fair value of $217.6 million . The Company's debt facilities are classified as a Level 3 in the fair value hierarchy. The calculation of the fair value is based on a discounted cash flow model using observable market inputs and taking into consideration variables such as interest rate changes, comparable instruments, and long-term credit ratings.

Deferred revenue

Deferred revenue	3 Months Ended
	Mar. 31, 2018
Revenue Recognition [Abstract]
Deferred revenue	Deferred revenue Short-term deferred revenue of $95.7 million and $78.8 million includes deferred revenue from product sales and service contracts, net of deferred cost of sales of $15.7 million and $16.9 million as of March 31, 2018 and December 31, 2017 , respectively. The short-term deferred revenues from product sales relate to delivered and invoiced products, pending installation and acceptance, expected to occur within the next twelve months. Long-term deferred revenue includes deferred revenue from service contracts of $8.8 million and $10.6 million , as of March 31, 2018 and December 31, 2017 , respectively.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Lease commitments The Company leases office space and office equipment under operating leases. Commitments under operating leases primarily relate to leasehold property and office equipment. At March 31, 2018 , the minimum future payments on non-cancelable operating leases were as follows: (In thousands) Remaining nine months of 2018 $ 8,896 2019 11,763 2020 10,803 2021 10,515 2022 8,818 Thereafter 26,383 Total minimum future lease payments $ 77,178 Purchase obligations In the ordinary course of business, the Company issues purchase orders based on its current manufacturing needs. At March 31, 2018 , the Company had non-cancelable purchase commitments of $55.4 million , which are expected to be paid within the next twelve months. Legal Proceedings The Company is currently involved in various legal proceedings. As required under ASC 450, Contingencies, the Company accrues for contingencies when it believes that a loss is probable and that it can reasonably estimate the amount of any such loss. The Company has not recorded any accrual for contingent liabilities associated with the legal proceedings described below based on its belief that any potential loss, while reasonably possible, is not probable. Further, any possible range of loss in these matters cannot be reasonably estimated at this time. The Company believes that it has valid defenses with respect to legal proceedings pending against it. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of this contingency or because of the diversion of management's attention and the creation of significant expenses. On January 10, 2018, a lawsuit was filed against a number of individuals, governmental agencies and corporate entities, including the Company and one of its subsidiaries, Aesynt Incorporated (“Aesynt”), in the Circuit Court for the City of Richmond, Virginia, captioned Ruth Ann Warner, as Guardian of Jonathan James Brewster Warner v. Centra Health, Inc., et al. (Case No. CL18-152-1). The complaint seeks monetary recovery of compensatory and punitive damages in addition to certain declaratory relief based upon, as against the individuals, governmental agencies and corporate entities other than the Company and Aesynt, allegations of the use of excessive force, unlawful detention, false imprisonment, battery, simple and gross negligence and negligent hiring, detention and training and, as against the Company and Aesynt, claims of product liability, negligence and breach of implied warranties. The Company and Aesynt have not yet been served with the complaint. The Company intends to defend the lawsuit vigorously.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes On December 22, 2017, the Tax Cuts and Jobs Act (the "Act") was signed into law, most provisions of which became effective starting in 2018, including the reduction of the statutory corporate income tax rate from 35% to 21%. As of March 31, 2018, the Company has not completed the accounting for the tax effects of enactment of the Act; however, in the fourth quarter of 2017, the Company made a reasonable estimate of the effects on the existing deferred tax balances and the one-time transition tax. No adjustments to the provisional amounts recorded in the fourth quarter of 2017 have been made during the three months ended March 31, 2018. In the current quarter, the Company assessed the effect of certain international provisions of the Act that became effective January 1, 2018, and determined that these provisions had an immaterial impact, therefore, the Company did not record any impact as a result of the assessment. The Company will continue to analyze the provision for income taxes under the Act as future guidance is issued. Any revisions will be treated in accordance with the measurement period guidance outlined in Staff Accounting Bulletin No. 118. The Company generally provides for income taxes in interim periods based on the estimated annual effective tax rate for the year, adjusting for discrete items in the quarter in which they arise. The annual effective tax rate before discrete items was 18% and 39% for the three months ended March 31, 2018 and March 31, 2017 , respectively. The 2018 annual effective tax rate differed from the statutory rate of 21% primarily due to the unfavorable impact of state income taxes, non-deductible expenses and non-deductible equity charges, which were partially offset by the favorable impact of the Research & Development credits and foreign rate differential. The 2017 annual effective tax rate differed from the statutory rate of 35% primarily due to the unfavorable impact of state income taxes, foreign rate differential, and non-deductible equity charges, which were partially offset by the domestic production activities deduction and the Research & Development credits. As of March 31, 2018 and December 31, 2017 , the Company had gross unrecognized tax benefits of $11.6 million and $10.7 million , respectively. It is the Company’s policy to classify accrued interest and penalties as part of the unrecognized tax benefits, but to record interest and penalties in operating expense. As of March 31, 2018 and December 31, 2017 , the amount of accrued interest and penalties was $1.5 million and $1.4 million , respectively. The Company files income tax returns in the United States and various states and foreign jurisdictions. In the normal course of business, the Company is subject to examination by taxing authorities, including major jurisdictions such as the United States, Germany, Italy, Netherlands and the United Kingdom. With few exceptions, as of March 31, 2018, the Company is no longer subject to U.S., state, and foreign examination for years before 2014, 2013, and 2014. Although the Company believes it has adequately provided for uncertain tax positions, the provisions on these positions may change as revised estimates are made or the underlying matters are settled or otherwise resolved. It is not possible at this time to reasonably estimate changes in the unrecognized tax benefits within the next twelve months.

Employee Benefits and Share-Bas

Employee Benefits and Share-Based Compensation	3 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Benefits and Share-Based Compensation	Employee Benefits and Share-Based Compensation Stock based plans For a detailed explanation of the Company's stock plans and subsequent changes, please refer to Note 11, Employee Benefits and Share-Based Compensation, of the Company's Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on February 27, 2018. Share-based compensation expense The following table sets forth the total share-based compensation expense recognized in the Company's Condensed Consolidated Statements of Operations: Three months ended March 31, 2018 March 31, 2017 (In thousands) Cost of product and service revenues $ 1,019 $ 982 Research and development 1,234 897 Selling, general and administrative 4,275 3,632 Total share-based compensation expense $ 6,528 $ 5,511 Stock Options and ESPP Shares The following assumptions were used to value share options and Employee Stock Purchase Plan ("ESPP") shares granted pursuant to the Company's equity incentive plans for the three months ended March 31, 2018 and 2017 : Three months ended March 31, 2018 March 31, 2017 Stock Option Plans Expected life, years 4.79 4.67 Expected volatility, % 32.2 % 31.1 % Risk free interest rate, % 2.57 % 1.89 % Estimated forfeiture rate % 6.9 % 7.7 % Dividend yield, % — % — % Three months ended March 31, 2018 March 31, 2017 Employee Stock Purchase Plan Expected life, years 0.5-2.0 0.5-2.0 Expected volatility, % 27.7-33.8% 25.8-32.8% Risk free interest rate, % 0.70-2.25% 0.52-1.31% Dividend yield, % — % — % Stock Options activity The following table summarizes the share option activity under the Company’s equity incentive plans during the three months ended March 31, 2018 : Number of Shares Weighted-Average Exercise Price Weighted-Average Remaining Years Aggregate Intrinsic Value (In thousands, except per share data) Stock Options Outstanding at December 31, 2017 3,323 $ 32.72 7.6 $ 53,953 Granted 482 44.38 Exercised (87 ) 22.50 Expired (1 ) 24.09 Forfeited (43 ) 37.14 Outstanding at March 31, 2018 3,674 $ 34.45 7.3 $ 37,607 Exercisable at March 31, 2018 1,474 $ 25.36 5.3 $ 26,596 Vested and expected to vest at March 31, 2018 and thereafter 3,456 $ 33.94 7.2 $ 36,818 The weighted-average fair value per share of options granted during the three months ended March 31, 2018 and 2017 was $14.22 and $10.86 , respectively. The intrinsic value of options exercised during the three months ended March 31, 2018 and 2017 was $2.0 million and $2.9 million , respectively. As of March 31, 2018 , total unrecognized compensation cost related to unvested stock options was $23.1 million , which is expected to be recognized over a weighted-average vesting period of 3.0 years. Employee Stock Purchase Plan activity For the three months ending March 31, 2018 and 2017 , employees purchased approximately 289,000 and 259,000 shares of common stock under the ESPP at weighted average prices of $26.30 and $25.51 , respectively. As of March 31, 2018 , the unrecognized compensation cost related to the shares to be purchased under the ESPP was approximately $6.5 million and is expected to be recognized over a weighted-average period of 1.4 years . Restricted Stock Units and Restricted Stock Awards Summaries of restricted stock activity under the Company's 2009 Equity Incentive Plan, as amended (the "2009 Plan") are presented below: Number of Shares Weighted-Average Grant Date Fair Value Weighted-Average Remaining Years Aggregate Intrinsic Value (In thousands, except per share data) Restricted Stock Units ("RSUs") Outstanding at December 31, 2017 501 $ 38.90 1.5 $ 24,293 Granted 71 44.32 Vested (50 ) 33.70 Forfeited (14 ) 39.05 Outstanding and unvested at March 31, 2018 508 $ 40.16 1.5 $ 22,041 The weighted-average grant date fair value per share of RSUs granted during the three months ended March 31, 2018 and March 31, 2017 was $44.32 and $36.57 , respectively. As of March 31, 2018 , total unrecognized compensation expense related to RSUs was $17.2 million , which is expected to be recognized over the remaining weighted-average vesting period of 2.8 years. Number of Shares Weighted-Average Grant Date Fair Value (In thousands, except per share data) Restricted Stock Awards ("RSAs") Outstanding at December 31, 2017 23 $ 41.07 Granted — — Vested — — Forfeited — — Outstanding and unvested at March 31, 2018 23 $ 41.08 As of March 31, 2018 , total unrecognized compensation cost related to RSAs was $0.1 million , which is expected to be recognized over the remaining weighted-average vesting period of 0.1 years . Performance-based Restricted Stock Units A summary of the performance-based restricted stock activity under the 2009 Plan during the three months ended March 31, 2018 is presented below: Number of Shares Weighted-Average Grant Date Fair Value Per Unit (In thousands, except per share data) Performance-based Restricted Stock Units ("PSUs") Outstanding at December 31, 2017 225 $ 31.18 Granted 110 38.03 Vested (32 ) 32.37 Forfeited (1 ) 43.20 Outstanding and unvested at March 31, 2018 302 $ 33.51 The weighted-average grant date fair value per share of PSUs granted during the three months ended March 31, 2018 and 2017 was $38.03 and $32.37 , respectively. As of March 31, 2018 , total unrecognized compensation cost related to PSUs was $5.4 million , which is expected to be recognized over the remaining weighted-average period of 1.5 years . Summary of Shares Reserved for Future Issuance under Equity Incentive Plans The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of March 31, 2018 : Number of Shares (In thousands) Share options outstanding 3,674 Non-vested restricted share awards 833 Shares authorized for future issuance 730 ESPP shares available for future issuance 2,077 Total shares reserved for future issuance 7,314 Stock Repurchase Program On August 2, 2016, the Company's Board of Directors (the "Board") authorized a stock repurchase program providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2016 Repurchase Program”). The 2016 Repurchase Program is in addition to the stock repurchase program approved by the Board on November 4, 2014 (the “2014 Repurchase Program”). As of March 31, 2018 , the maximum dollar value of shares that may yet be purchased under the two repurchase programs was $54.9 million . The stock repurchase programs do not obligate the Company to repurchase any specific number of shares, and the Company may terminate or suspend the repurchase program at any time. During the three months ended March 31, 2018 and 2017 , the Company did not repurchase any of its outstanding common stock.

Equity Offerings

Equity Offerings	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Equity Offerings	Equity Offerings On November 3, 2017, the Company entered into a Distribution Agreement (the “Distribution Agreement”) with J.P. Morgan Securities LLC, Wells Fargo Securities, LLC and HSBC Securities (USA) Inc., as its sales agents, pursuant to which the Company may offer and sell from time to time through the sales agents up to $125 million maximum aggregate offering price of the Company’s common stock. Sales of the common stock pursuant to the Distribution Agreement may be made in negotiated transactions or transactions that are deemed to be “at the market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended (the "Securities Act"), including sales made directly on the Nasdaq Stock Market, or sales made to or through a market maker other than on an exchange. For the three months ended March 31, 2018, the Company did not sell any of its common stock under the Distribution Agreement.

Segment and Geographical Inform

Segment and Geographical Information	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Segment and Geographical Information	Segment and Geographical Information The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company's segments using information about its revenues, gross profit, and income from operations. Such evaluation excludes general corporate-level costs that are not specific to either of the reportable segments and are managed separately at the corporate level. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain administrative expenses. The two operating segments, which are the same as the Company's two reportable segments, are as follows: Automation and Analytics The Automation and Analytics segment is organized around the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems, and related software. The Automation and Analytics products are designed to enable the Company's customers to enhance and improve the effectiveness of the medication-use process, the efficiency of the medical-surgical supply chain, overall patient care and clinical and financial outcomes of medical facilities. Through modular configuration and upgrades, the Company's systems can be tailored to specific customer needs. The financial results of InPharmics acquired in the second quarter of 2017 are included in the Automation and Analytics segment. Medication Adherence The Medication Adherence segment includes solutions to assist patients to remain adherent to their medication regimens. These solutions are comprised of a variety of tools and aids that may be directly used by a pharmacist or a healthcare provider in their direct care for a patient, or the patient themselves, and include software based systems and medication adherence packaging. Software solutions primarily operate on the Patient Management Access Portal (PMAP), a subscription based software system which provides an environment for patient engagement by clinicians. Services running on PMAP include Time My Meds ® medication synchronization, immunization management, and a number of tools used by clinicians to manage patient engagement workflows. Medication Adherence packaging is designed either for patient use in care environments where there is a caregiver present or for environments where the patient cares for him or herself and includes the manufacturing and selling of consumable medication blister cards, packaging equipment and ancillary products and services. The following tables summarize the financial performance of the Company's reportable segments, including a reconciliation of income from segment operations to income from total operations: Three months ended March 31, 2018 2017 Automation and Medication Total Automation and Medication Total (In thousands) Revenues $ 151,406 $ 31,213 $ 182,619 $ 122,170 $ 26,383 $ 148,553 Cost of revenues 78,242 21,922 100,164 68,761 17,601 86,362 Gross profit 73,164 9,291 82,455 53,409 8,782 62,191 Operating expenses 48,390 10,199 58,589 48,062 11,196 59,258 Income from operations $ 24,774 $ (908 ) $ 23,866 $ 5,347 $ (2,414 ) $ 2,933 Corporate costs 23,233 19,485 Income from operations $ 633 $ (16,552 ) Significant customers There were no customers that accounted for more than 10% of our total revenues for the three months ended March 31, 2018 and 2017 . Also, there were no customers that accounted for more than 10% of our accounts receivable as of March 31, 2018 and December 31, 2017 . Geographical Information Revenues Three months ended March 31, 2018 2017 (In thousands) United States $ 158,202 $ 130,279 Rest of world (1) 24,417 18,274 Total revenues $ 182,619 $ 148,553 _________________________________________________ (1) No individual country represented more than 10% of the respective totals. Property and equipment, net March 31, December 31, (In thousands) United States $ 40,116 $ 34,899 Rest of world (1) 8,174 7,696 Total property and equipment, net $ 48,290 $ 42,595 _________________________________________________ (1) No individual country represented more than 10% of the respective totals. Property and equipment, net is attributed to the geographic location in which it is located.

Restructuring Expenses

Restructuring Expenses	3 Months Ended
	Mar. 31, 2018
Restructuring and Related Activities [Abstract]
Restructuring Expenses	Restructuring Expenses On March 2, 2018, the Company initiated the realignment of its Automation and Analytics commercial group in North American and France. The total estimated cost for the plan was $1.5 million and consists primarily of employee severance cost. As of March 31, 2018, the unpaid balance is $1.4 million and is presented as a component of accrued compensation liabilities in the Condensed Consolidated Balance Sheet. On February 15, 2017, the Company announced its plan to reduce its workforce by approximately 100 full-time employees and close the Company’s Nashville, Tennessee and Slovenia facilities. The plan was completed in fiscal year 2017. During the three months ended March 31, 2017, the Company accrued $3.8 million of expenses, primarily for employee severance and related expenses, and paid out $2.1 million . The remaining unpaid balance of $1.7 million accrued expenses is presented as a component of accrued compensation in the Condensed Consolidated Balance Sheet. There were no facility-related costs incurred during the three months ended March 31, 2017.

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event On April 30, 2018, the Company entered into a settlement agreement related to certain contingencies associated with the Ateb 2016 acquisition. The settlement, which will be recognized in the second quarter of 2018, is for approximately $2.5 million .

Organization and Summary of S23

Organization and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of March 31, 2018 and December 31, 2017 , the results of its operations, comprehensive income (loss) and cash flows for the three months ended March 31, 2018 and March 31, 2017 . Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in the Company's annual report on Form 10-K for the year ended December 31, 2017 filed with the SEC on February 27, 2018, except as discussed in the "Revenue recognition" below. The Company's results of operations, comprehensive income (loss) and cash flows for the three months ended March 31, 2018 are not necessarily indicative of results that may be expected for the year ending December 31, 2018 , or for any future period.
Principles of consolidation	Principles of consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company's Condensed Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company's critical accounting policies are those that affect its financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, accounts receivable and notes receivable from investment in sales-type leases, inventory valuation, capitalized software development costs, valuation and impairment of goodwill, purchased intangibles and long-lived assets, fair value of assets acquired and liabilities assumed in business combination, share-based compensation, and accounting for income taxes.
Segment reporting	Segment reporting The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company's segments using information about its revenues, gross profit, and income from operations. Such evaluation excludes general corporate-level costs that are not specific to either of the reportable segments and are managed separately at the corporate level. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain other administrative expenses. See Note 14, Segment and Geographical Information, for additional information on segment reporting.
Recently adopted and issued authoritative guidance	Recently adopted authoritative guidance In May 2014, the Financial Accounting Standards Board ("FASB") issued ASC 606, Revenue from Contracts with Customer s, a new standard related to revenue recognition. Under the new standard, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective method). We adopted the standard using the full retrospective method effective beginning January 1, 2018. Under the ASC 606 guidance, fees paid to GPOs are now presented as a reduction of Product Revenue, whereas these fees were considered a part of Selling, General and Administrative costs under the previous guidance. The majority of the incremental costs incurred to obtain a contract, primarily commission expense, are recognized during the first year with the balance recognized ratably over a period of ten years. Additionally, revenue on term software licenses is recognized upon installation of the license rather than ratably over the life of the term license. Finally, the Company no longer defers the contingent revenue in transactions where the amount charged to the customer for a particular performance obligation is less than the allocation of standalone selling price. Adoption of the standard related to revenue recognition impacted our reported results for the three months period, as follows: March 31, 2017 As reported Adjustment As adjusted (In thousands) Revenue Automation and Analytics $ 124,171 $ (2,001 ) $ 122,170 Medication Adherence 26,383 — 26,383 Gross profit Automation and Analytics 55,410 (2,001 ) 53,409 Medication Adherence 8,782 — 8,782 Selling, general and administrative expenses 64,625 (2,685 ) 61,940 Provision for income taxes (8,938 ) 265 (8,673 ) Net income $ (10,754 ) $ 419 $ (10,335 ) Earnings per share $ (0.29 ) $ 0.01 $ (0.28 ) December 31, 2017 As reported Adjustment As adjusted (In thousands) Accounts receivable and unbilled, net $ 189,227 $ 819 $ 190,046 Prepaid expenses 36,060 (15,668 ) 20,392 Prepaid commissions — 41,432 41,432 Other long-term assets 39,841 9,475 49,316 Deferred revenue, net 86,104 (7,330 ) 78,774 Long-term, deferred revenue 17,244 (6,621 ) 10,623 Long-term, deferred tax liabilities 28,579 12,867 41,446 Stockholders' equity 517,199 37,142 554,341 Recently issued authoritative guidance In February 2018, the FASB issued ASU 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which permits the reclassification of the income tax effects of the Tax Cuts and Jobs Act of 2017 on items within accumulated other comprehensive income to retained earnings. These amounts are commonly referred to as “stranded tax effects”. ASU 2018-02 will be effective for the Company beginning January 1, 2019. The Company is currently in the process of evaluating the impact of adoption on the consolidated financial statements.

Organization and Summary of S24

Organization and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Contract with Customer, Asset and Liability	The following table reflects the Company’s contract assets and contract liabilities: March 31, December 31, (In thousands) Short-term unbilled receivable - included in accounts receivable and unbilled $ 4,859 $ 4,590 Long-term unbilled receivable - included in other long-term assets 10,877 9,475 Total contract assets $ 15,736 $ 14,065 Short-term deferred revenue $ 95,709 $ 78,774 Long-term deferred revenue 8,806 10,623 Total contract liabilities $ 104,515 $ 89,397
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	March 31, 2017 As reported Adjustment As adjusted (In thousands) Revenue Automation and Analytics $ 124,171 $ (2,001 ) $ 122,170 Medication Adherence 26,383 — 26,383 Gross profit Automation and Analytics 55,410 (2,001 ) 53,409 Medication Adherence 8,782 — 8,782 Selling, general and administrative expenses 64,625 (2,685 ) 61,940 Provision for income taxes (8,938 ) 265 (8,673 ) Net income $ (10,754 ) $ 419 $ (10,335 ) Earnings per share $ (0.29 ) $ 0.01 $ (0.28 ) December 31, 2017 As reported Adjustment As adjusted (In thousands) Accounts receivable and unbilled, net $ 189,227 $ 819 $ 190,046 Prepaid expenses 36,060 (15,668 ) 20,392 Prepaid commissions — 41,432 41,432 Other long-term assets 39,841 9,475 49,316 Deferred revenue, net 86,104 (7,330 ) 78,774 Long-term, deferred revenue 17,244 (6,621 ) 10,623 Long-term, deferred tax liabilities 28,579 12,867 41,446 Stockholders' equity 517,199 37,142 554,341

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Basic and Diluted Net Income Per Share	The basic and diluted net income (loss) per share calculation for the three months ended March 31, 2018 and 2017 was as follows: Three months ended March 31, 2018 2017 (In thousands, except per share data) Net income (loss) $ 2,720 $ (10,335 ) Weighted-average shares outstanding — basic 38,635 36,840 Effect of dilutive securities from stock award plans 1,056 — Weighted-average shares outstanding — diluted $ 39,691 $ 36,840 Net income (loss) per share - basic $ 0.07 $ (0.28 ) Net income (loss) per share - diluted $ 0.07 $ (0.28 ) Anti-dilutive weighted-average shares related to stock award plans 1,113 4,236

Cash and Cash Equivalents and26

Cash and Cash Equivalents and Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Schedule of Financial Assets Measured At Fair Value	The following table represents the fair value hierarchy of the Company’s financial assets and financial liabilities measured at fair value as of March 31, 2018 : Level 1 Level 2 Level 3 Total (In thousands) Interest rate swap contracts $ — $ 1,464 $ — $ 1,464 Total financial assets $ — $ 1,464 $ — $ 1,464 There were no transfers between fair value measurement levels during the three months ended March 31, 2018 and March 31, 2017 . The following table represents the fair value hierarchy of the Company’s financial assets and financial liabilities measured at fair value as of December 31, 2017 : Level 1 Level 2 Level 3 Total (In thousands) Interest rate swap contracts $ — $ 1,378 $ — $ 1,378 Total financial assets $ — $ 1,378 $ — $ 1,378

Balance Sheet Components (Table

Balance Sheet Components (Tables)	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Balance Sheet	Balance sheet details as of March 31, 2018 and December 31, 2017 are presented in the tables below: March 31, December 31, (In thousands) Inventories: Raw materials $ 25,103 $ 22,750 Work in process 9,959 9,818 Finished goods and service parts 66,806 63,569 Total inventories $ 101,868 $ 96,137 Property and equipment: Equipment $ 72,122 $ 69,550 Furniture and fixtures 6,750 6,534 Leasehold improvements 14,540 10,976 Software 38,840 37,168 Construction in progress 11,334 9,813 Property and equipment, gross 143,586 134,041 Accumulated depreciation and amortization (95,296 ) (91,446 ) Total property and equipment, net $ 48,290 $ 42,595 Other long term assets: Capitalized software, net $ 41,146 $ 38,599 Unbilled receivable 10,877 9,475 Other assets 1,469 1,242 Total other long term assets, net $ 53,492 $ 49,316 March 31, December 31, Accrued liabilities: Advance payments from customers $ 6,879 $ 7,779 Rebates and lease buyouts 5,342 5,428 Group purchasing organization fees 3,439 3,449 Taxes payable 12,135 9,183 Other accrued liabilities 12,724 9,854 Total accrued liabilities $ 40,519 $ 35,693
Schedule of Accumulated Other Comprehensive Income (Loss)	The following table summarizes the changes in accumulated balances of other comprehensive income (loss) for the three months ended March 31, 2018 and 2017 : Three months ended March 31, 2018 2017 Foreign currency translation adjustments Unrealized gain (loss) on interest rate swap hedges Total Foreign currency translation adjustments Unrealized gain (loss) on interest rate swap hedges Total (In thousands) Beginning balance $ (6,954 ) $ 841 $ (6,113 ) $ (10,764 ) $ 1,245 $ (9,519 ) Other comprehensive income (loss) before reclassifications 2,472 401 2,873 923 176 1,099 Amounts reclassified from other comprehensive income (loss), net of tax (199 ) (199 ) — 6 6 Net current-period other comprehensive income (loss), net of tax 2,472 202 2,674 923 182 1,105 Ending balance $ (4,482 ) $ 1,043 $ (3,439 ) $ (9,841 ) $ 1,427 $ (8,414 )

Net Investment in Sales-Type 28

Net Investment in Sales-Type Leases (Tables)	3 Months Ended
	Mar. 31, 2018
Leases [Abstract]
Schedule of Long Term Net Investment in Sale-Type Leases	The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at March 31, 2018 and December 31, 2017 : March 31, December 31, (In thousands) Net minimum lease payments to be received $ 26,789 $ 25,899 Less: Unearned interest income portion (2,056 ) (1,695 ) Net investment in sales-type leases 24,733 24,204 Less: Short-term portion (1) (8,289 ) (8,769 ) Long-term net investment in sales-type leases $ 16,444 $ 15,435 (1) The short-term portion of the net investments in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets.
Schedule of Net Sale-Type Leases Minimum Lease Receivables	At March 31, 2018 , the future minimum lease payments under sales-type leases were as follows: March 31, (In thousands) Remaining nine months of 2018 $ 5,293 2019 7,872 2020 1,938 2021 5,203 2022 3,386 Thereafter 3,097 Total $ 26,789

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Carrying Amount of Goodwill	The following table represents changes in the carrying amount of goodwill: Automation and Analytics Medication Adherence Total (In thousands) Net balance as of December 31, 2017 $ 220,851 $ 116,900 $ 337,751 Foreign currency exchange rate fluctuations 831 366 1,197 Net balance as of March 31, 2018 $ 221,682 $ 117,266 $ 338,948
Intangible Assets, Net	The carrying amounts of intangible assets as of March 31, 2018 and December 31, 2017 were as follows: March 31, 2018 Gross carrying amount Accumulated amortization Foreign currency exchange rate fluctuations Net carrying amount Useful life (years) (In thousands, except for years) Customer relationships $ 133,950 $ (36,356 ) $ 314 $ 97,908 1 - 30 Acquired technology 74,371 (23,359 ) 203 51,215 3 - 20 Backlog 21,712 (18,424 ) — 3,288 1 - 4 Trade names 8,662 (4,861 ) 38 3,839 1 - 12 Patents 3,236 (1,390 ) 12 1,858 2 - 20 Non-compete agreements 1,900 (1,450 ) — 450 3 In-process technology 3,900 — — 3,900 — Total intangibles assets, net $ 247,731 $ (85,840 ) $ 567 $ 162,458 December 31, 2017 Gross carrying amount Accumulated amortization Foreign currency exchange rate fluctuations Net carrying amount Useful life (years) (In thousands, except for years) Customer relationships $ 133,913 $ (33,526 ) $ 65 $ 100,452 1 - 30 Acquired technology 74,593 (21,523 ) 34 53,104 3 - 20 Backlog 21,712 (17,544 ) — 4,168 1 - 5 Trade names 8,716 (4,719 ) 6 4,003 1 - 12 Patents 3,296 (1,418 ) 2 1,880 2 - 20 Non-compete agreements 1,900 (1,300 ) — 600 3 In-process technology 3,900 — — 3,900 — Total intangibles assets, net $ 248,030 $ (80,030 ) $ 107 $ 168,107
Future Amortization Expense for Intangible Assets	The estimated future amortization expenses for amortizable intangible assets are as follows: March 31, 2018 (In thousands) Remaining nine months of 2018 $ 17,463 2019 18,036 2020 16,832 2021 15,378 2022 14,009 Thereafter (excluding in-process technology) 76,840 Total $ 158,558

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Schedule of Debt	The components of the Company’s debt obligations as of March 31, 2018 and December 31, 2017 are as follows: December 31, 2017 Borrowings Repayment / Amortization March 31, 2018 (In thousands) Term loan facility $ 182,500 $ — $ (2,500 ) $ 180,000 Revolving credit facility 34,500 — — 34,500 Total debt under the facilities 217,000 — (2,500 ) 214,500 Less: Deferred issuance cost (6,875 ) — 573 (6,302 ) Total Debt, net of deferred issuance cost $ 210,125 $ — $ (1,927 ) $ 208,198 Long term debt, current portion, net of deferred issuance cost 15,208 17,708 Long term debt, net of deferred issuance cost $ 194,917 $ 190,490

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Minimum Future Payments on Non-Cancelable Operating Leases	At March 31, 2018 , the minimum future payments on non-cancelable operating leases were as follows: (In thousands) Remaining nine months of 2018 $ 8,896 2019 11,763 2020 10,803 2021 10,515 2022 8,818 Thereafter 26,383 Total minimum future lease payments $ 77,178

Employee Benefits and Share-B32

Employee Benefits and Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation Expense Recognized in Consolidate Statements of Income	The following table sets forth the total share-based compensation expense recognized in the Company's Condensed Consolidated Statements of Operations: Three months ended March 31, 2018 March 31, 2017 (In thousands) Cost of product and service revenues $ 1,019 $ 982 Research and development 1,234 897 Selling, general and administrative 4,275 3,632 Total share-based compensation expense $ 6,528 $ 5,511
Estimate of Fair Value of Share-Based Awards, Share Options	The following assumptions were used to value share options and Employee Stock Purchase Plan ("ESPP") shares granted pursuant to the Company's equity incentive plans for the three months ended March 31, 2018 and 2017 : Three months ended March 31, 2018 March 31, 2017 Stock Option Plans Expected life, years 4.79 4.67 Expected volatility, % 32.2 % 31.1 % Risk free interest rate, % 2.57 % 1.89 % Estimated forfeiture rate % 6.9 % 7.7 % Dividend yield, % — % — %
Estimate of Fair Value of Share-Based Awards, Employee Stock Purchase Plan	Three months ended March 31, 2018 March 31, 2017 Employee Stock Purchase Plan Expected life, years 0.5-2.0 0.5-2.0 Expected volatility, % 27.7-33.8% 25.8-32.8% Risk free interest rate, % 0.70-2.25% 0.52-1.31% Dividend yield, % — % — %
Stock Option Activity under the Equity Incentive Plans	The following table summarizes the share option activity under the Company’s equity incentive plans during the three months ended March 31, 2018 : Number of Shares Weighted-Average Exercise Price Weighted-Average Remaining Years Aggregate Intrinsic Value (In thousands, except per share data) Stock Options Outstanding at December 31, 2017 3,323 $ 32.72 7.6 $ 53,953 Granted 482 44.38 Exercised (87 ) 22.50 Expired (1 ) 24.09 Forfeited (43 ) 37.14 Outstanding at March 31, 2018 3,674 $ 34.45 7.3 $ 37,607 Exercisable at March 31, 2018 1,474 $ 25.36 5.3 $ 26,596 Vested and expected to vest at March 31, 2018 and thereafter 3,456 $ 33.94 7.2 $ 36,818
Restricted Stock Units Activity under the Stock Option Activity under the Equity Incentive Plans	Summaries of restricted stock activity under the Company's 2009 Equity Incentive Plan, as amended (the "2009 Plan") are presented below: Number of Shares Weighted-Average Grant Date Fair Value Weighted-Average Remaining Years Aggregate Intrinsic Value (In thousands, except per share data) Restricted Stock Units ("RSUs") Outstanding at December 31, 2017 501 $ 38.90 1.5 $ 24,293 Granted 71 44.32 Vested (50 ) 33.70 Forfeited (14 ) 39.05 Outstanding and unvested at March 31, 2018 508 $ 40.16 1.5 $ 22,041
Restricted Stock Units Award under the Stock Option Activity under the Equity Incentive Plans	Number of Shares Weighted-Average Grant Date Fair Value (In thousands, except per share data) Restricted Stock Awards ("RSAs") Outstanding at December 31, 2017 23 $ 41.07 Granted — — Vested — — Forfeited — — Outstanding and unvested at March 31, 2018 23 $ 41.08
Performance Shares Restricted Stock Activity under the Stock Option Activity under the Equity Incentive Plans	A summary of the performance-based restricted stock activity under the 2009 Plan during the three months ended March 31, 2018 is presented below: Number of Shares Weighted-Average Grant Date Fair Value Per Unit (In thousands, except per share data) Performance-based Restricted Stock Units ("PSUs") Outstanding at December 31, 2017 225 $ 31.18 Granted 110 38.03 Vested (32 ) 32.37 Forfeited (1 ) 43.20 Outstanding and unvested at March 31, 2018 302 $ 33.51
Shares Reserved for Future Issuance under the Stock Option Activity under the Equity Incentive Plans	The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of March 31, 2018 : Number of Shares (In thousands) Share options outstanding 3,674 Non-vested restricted share awards 833 Shares authorized for future issuance 730 ESPP shares available for future issuance 2,077 Total shares reserved for future issuance 7,314

Segment and Geographical Info33

Segment and Geographical Information (Tables)	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Financial Performance of Reporting Segments	The following tables summarize the financial performance of the Company's reportable segments, including a reconciliation of income from segment operations to income from total operations: Three months ended March 31, 2018 2017 Automation and Medication Total Automation and Medication Total (In thousands) Revenues $ 151,406 $ 31,213 $ 182,619 $ 122,170 $ 26,383 $ 148,553 Cost of revenues 78,242 21,922 100,164 68,761 17,601 86,362 Gross profit 73,164 9,291 82,455 53,409 8,782 62,191 Operating expenses 48,390 10,199 58,589 48,062 11,196 59,258 Income from operations $ 24,774 $ (908 ) $ 23,866 $ 5,347 $ (2,414 ) $ 2,933 Corporate costs 23,233 19,485 Income from operations $ 633 $ (16,552 )
Revenue by Geographical Location	Revenues Three months ended March 31, 2018 2017 (In thousands) United States $ 158,202 $ 130,279 Rest of world (1) 24,417 18,274 Total revenues $ 182,619 $ 148,553 _________________________________________________ (1) No individual country represented more than 10% of the respective totals.
Long-lived Assets by Geographical Location	Property and equipment, net March 31, December 31, (In thousands) United States $ 40,116 $ 34,899 Rest of world (1) 8,174 7,696 Total property and equipment, net $ 48,290 $ 42,595 _________________________________________________ (1) No individual country represented more than 10% of the respective totals.

Organization and Summary of S34

Organization and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Transaction price allocated to unsatisfied performance obligation	$ 104,500,000		$ 89,400,000
Transaction price allocated to unsatisfied performance obligation, current	95,709,000		$ 78,774,000
Revenue from sales-type leases	9,800,000	$ 3,200,000
Fees to GPOs	1,900,000	2,100,000
Deferred revenue recognized	46,600,000
Capitalized commissions	5,600,000	$ 4,100,000
Impairment loss	$ 0

Organization and Summary of S35

Organization and Summary of Significant Accounting Policies - Contract Assets and Contract Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Short-term unbilled receivable - included in accounts receivable and unbilled	$ 4,859	$ 4,590
Long-term unbilled receivable - included in other long-term assets	10,877	9,475
Total contract assets	15,736	14,065
Short-term deferred revenue	95,709	78,774
Long-term deferred revenue	8,806	10,623
Total contract liabilities	$ 104,515	$ 89,397

Organization and Summary of S36

Organization and Summary of Significant Accounting Policies - Impact of Newly Adopted Standard Related to Revenue Recognition (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenues	$ 182,619	$ 148,553
Gross profit	82,455	62,191
Selling, general and administrative	65,285	61,940
Provision for income taxes	(4,816)	(8,673)
Net income (loss)	$ 2,720	$ (10,335)
Earnings per share	$ 0.07	$ (0.28)
Accounts receivable and unbilled, net	$ 190,678		$ 190,046
Prepaid expenses	21,161		20,392
Prepaid commissions	39,636		41,432
Other long-term assets	53,492		49,316
Short-term deferred revenue	95,709		78,774
Long-term deferred revenue	8,806		10,623
Long-term deferred tax liabilities	36,320		41,446
Stockholders' equity	574,502		554,341
Automation and analytics
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenues		$ 122,170
Gross profit		53,409
Medication adherence
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenues		26,383
Gross profit		$ 8,782
Scenario, Previously Reported
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Provision for income taxes	(8,938)
Net income (loss)	$ (10,754)
Earnings per share	$ (0.29)
Accounts receivable and unbilled, net			189,227
Prepaid expenses			36,060
Prepaid commissions			0
Other long-term assets			39,841
Short-term deferred revenue			86,104
Long-term deferred revenue			17,244
Long-term deferred tax liabilities			28,579
Stockholders' equity			517,199
Scenario, Previously Reported | Automation and analytics
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenues	$ 124,171
Gross profit	55,410
Scenario, Previously Reported | Medication adherence
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenues	26,383
Gross profit	8,782
Selling, general and administrative	64,625
Accounting Standards Update 2014-09 | Restatement Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Provision for income taxes	265
Net income (loss)	$ 419
Earnings per share	$ 0.01
Accounts receivable and unbilled, net			819
Prepaid expenses			(15,668)
Prepaid commissions			41,432
Other long-term assets			9,475
Short-term deferred revenue			(7,330)
Long-term deferred revenue			(6,621)
Long-term deferred tax liabilities			12,867
Stockholders' equity			$ 37,142
Accounting Standards Update 2014-09 | Restatement Adjustment | Automation and analytics
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenues	$ (2,001)
Gross profit	(2,001)
Accounting Standards Update 2014-09 | Restatement Adjustment | Medication adherence
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenues	0
Gross profit	0
Selling, general and administrative	$ (2,685)

Business Acquisitions - Additio

Business Acquisitions - Additional Information (Details) - InPharmics LLC $ in Millions	Apr. 12, 2017USD ($)
Business Acquisition [Line Items]
Total purchase price, net of cash received	$ 5
Cash on hand at signing	0.3
Contingent consideration liability	0.5
Intangibles	$ 1.9

Net Income (Loss) Per Share (De

Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Earnings Per Share [Abstract]
Net income (loss)	$ 2,720	$ (10,335)
Weighted-average shares outstanding — basic (in shares)	38,635	36,840
Effect of dilutive securities from stock award plans (in shares)	1,056	0
Weighted-average shares outstanding — diluted (in shares)	39,691	36,840
Net income (loss) per share - basic (in dollars per share)	$ 0.07	$ (0.28)
Net income (loss) per share - diluted (in dollars per share)	$ 0.07	$ (0.28)
Anti-dilutive weighted-average shares related to stock award plans (in shares)	1,113	4,236

Cash and Cash Equivalents and39

Cash and Cash Equivalents and Fair Value of Financial Instruments - Narrative (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 43,773	$ 32,424	$ 46,348	$ 54,488
Assets, Fair Value Disclosure		$ 1,378	$ 1,464
Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount				$ 100,000
Derivative, fixed interest rate				0.80%
London Interbank Offered Rate (LIBOR) | Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, basis spread on variable rate				0.00%

Cash and Cash Equivalents and40

Cash and Cash Equivalents and Fair Value of Financial Instruments - Schedule of Financial Assets Measured At Fair Value (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Mar. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap contracts	$ 1,378	$ 1,464
Total financial assets	1,378	1,464
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap contracts	0	0
Total financial assets	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap contracts	1,378	1,464
Total financial assets	1,378	1,464
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap contracts	0	0
Total financial assets	$ 0	$ 0

Balance Sheet Components - Bala

Balance Sheet Components - Balance Sheet Details (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Inventories:
Raw materials		$ 22,750	$ 25,103
Work in process		9,818	9,959
Finished goods		63,569	66,806
Total inventories	$ 101,868	96,137	$ 101,868
Property and equipment:
Equipment	72,122	69,550
Furniture and fixtures	6,750	6,534
Leasehold improvements	14,540	10,976
Software	38,840	37,168
Construction in progress	11,334	9,813
Property and equipment, gross	143,586	134,041
Accumulated depreciation and amortization	(95,296)	(91,446)
Total property and equipment, net	48,290	42,595
Other long term assets:
Capitalized software, net	41,146	38,599
Unbilled receivable	10,877	9,475
Other assets	1,469	1,242
Total other long term assets, net	53,492	49,316
Accrued liabilities:
Advance payments from customers	6,879	7,779
Rebates and lease buyouts	5,342	5,428
Group purchasing organization fees	3,439	3,449
Taxes payable	12,135	9,183
Other accrued liabilities	12,724	9,854
Total accrued liabilities	$ 40,519	$ 35,693

Balance Sheet Components - Accu

Balance Sheet Components - Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 554,341
Other comprehensive income (loss) before reclassifications	2,873	$ 1,099
Amounts reclassified from other comprehensive income (loss), net of tax	(199)	6
Net current-period other comprehensive income (loss), net of tax	2,674	1,105
Ending balance	574,502
Foreign currency translation adjustments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(6,954)	(10,764)
Other comprehensive income (loss) before reclassifications	2,472	923
Amounts reclassified from other comprehensive income (loss), net of tax		0
Net current-period other comprehensive income (loss), net of tax	2,472	923
Ending balance	(4,482)	(9,841)
Unrealized gain (loss) on interest rate swap hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	841	1,245
Other comprehensive income (loss) before reclassifications	401	176
Amounts reclassified from other comprehensive income (loss), net of tax	(199)	6
Net current-period other comprehensive income (loss), net of tax	202	182
Ending balance	1,043	1,427
AOCI Attributable to Parent
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(6,113)	(9,519)
Ending balance	$ (3,439)	$ (8,414)

Net Investment in Sales-Type 43

Net Investment in Sales-Type Leases - Long Term Net Investment in Sales Type Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Capital Leased Assets [Line Items]
Net minimum lease payments to be received	$ 26,789	$ 25,899
Less: Unearned interest income portion	(2,056)	(1,695)
Net investment in sales-type leases	24,733	24,204
Less: Short-term portion	(8,289)	(8,769)
Long-term investment in sales-type leases, net	16,444	15,435
Collective allowance for credit losses	$ 200	$ 200
Minimum
Capital Leased Assets [Line Items]
Terms of sales-type leases (generally up to five years in length) (in years)	1 year
Maximum
Capital Leased Assets [Line Items]
Terms of sales-type leases (generally up to five years in length) (in years)	5 years

Net Investment in Sales-Type 44

Net Investment in Sales-Type Leases - Capital Leases, Future Minimum Payments Receivable (Details) $ in Thousands	Mar. 31, 2018USD ($)
Leases [Abstract]
Remaining nine months of 2018	$ 5,293
2,019	7,872
2,020	1,938
2,021	5,203
2,022	3,386
Thereafter	3,097
Total	$ 26,789

Goodwill and Intangible Asset45

Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 337,751
Foreign currency exchange rate fluctuations	1,197
Ending balance	338,948
Automation and analytics
Goodwill [Roll Forward]
Beginning balance	220,851
Foreign currency exchange rate fluctuations	831
Ending balance	221,682
Medication adherence
Goodwill [Roll Forward]
Beginning balance	116,900
Foreign currency exchange rate fluctuations	366
Ending balance	$ 117,266

Goodwill and Intangible Asset46

Goodwill and Intangible Assets - Intangible Assets, Net (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Acquired Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	$ (85,840)	$ (80,030)
Foreign currency exchange rate fluctuations	567	107
Total intangibles assets, gross carrying amount	247,731	248,030
Total intangible assets, net carrying amount	162,458	168,107
In-process technology
Acquired Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	0	0
Foreign currency exchange rate fluctuations	0	0
Indefinite-lived intangible assets	3,900	3,900
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	133,950	133,913
Accumulated amortization	(36,356)	(33,526)
Foreign currency exchange rate fluctuations	314	65
Net carrying amount	$ 97,908	$ 100,452
Customer relationships | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	1 year	1 year
Customer relationships | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	30 years	30 years
Acquired technology
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 74,371	$ 74,593
Accumulated amortization	(23,359)	(21,523)
Foreign currency exchange rate fluctuations	203	34
Net carrying amount	$ 51,215	$ 53,104
Acquired technology | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	3 years	3 years
Acquired technology | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	20 years	20 years
Backlog
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 21,712	$ 21,712
Accumulated amortization	(18,424)	(17,544)
Foreign currency exchange rate fluctuations	0	0
Net carrying amount	$ 3,288	$ 4,168
Backlog | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	1 year	1 year
Backlog | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	4 years	5 years
Trade names
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 8,662	$ 8,716
Accumulated amortization	(4,861)	(4,719)
Foreign currency exchange rate fluctuations	38	6
Net carrying amount	$ 3,839	$ 4,003
Trade names | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	1 year	1 year
Trade names | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	12 years	12 years
Patents
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 3,236	$ 3,296
Accumulated amortization	(1,390)	(1,418)
Foreign currency exchange rate fluctuations	12	2
Net carrying amount	$ 1,858	$ 1,880
Patents | Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	2 years	2 years
Patents | Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	20 years	20 years
Non-compete agreements
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 1,900	$ 1,900
Accumulated amortization	(1,450)	(1,300)
Foreign currency exchange rate fluctuations	0	0
Net carrying amount	$ 450	$ 600
Useful life (in years)	3 years	3 years

Goodwill and Intangible Asset47

Goodwill and Intangible Assets - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense of intangible assets	$ 6	$ 6.5

Goodwill and Intangible Asset48

Goodwill and Intangible Assets - Future Amortization Expense for Intangible Assets (Details) $ in Thousands	Mar. 31, 2018USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remaining nine months of 2018	$ 17,463
2,018	18,036
2,019	16,832
2,020	15,378
2,021	14,009
Thereafter (excluding in-process technology)	76,840
Net carrying amount	$ 158,558

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($)	Jan. 05, 2016	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Dec. 31, 2017	Dec. 26, 2017	Apr. 11, 2017
Debt Instrument [Line Items]
Repayment of debt and revolving credit facility		$ 2,500,000	$ 40,000,000
Interest expense		1,900,000	1,500,000
Amortization of debt financing fees		573,000	$ 397,000
Wells Fargo Bank, National Association
Debt Instrument [Line Items]
Proceeds from lines of credit		0
Repayment of debt and revolving credit facility		2,500,000		$ 139,500,000
Amortization of debt financing fees		573,000
Carry amount of debt		214,500,000		214,500,000	$ 217,000,000
Fair value of debt		217,600,000		217,600,000
Wells Fargo Bank, National Association | Secured Debt | Line of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 400,000,000
Annual capital expenditure limitation per Credit Agreement	35,000,000						$ 45,000,000
Maximum allowed non-permitted investments per Credit Agreement	10,000,000						$ 20,000,000
Deferred issuance cost, gross	$ 10,100,000
Wells Fargo Bank, National Association | Secured Debt | Line of Credit | Credit Agreement, Interest Rate Option One | London Interbank Offered Rate (LIBOR) | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	1.50%
Wells Fargo Bank, National Association | Secured Debt | Line of Credit | Credit Agreement, Interest Rate Option One | London Interbank Offered Rate (LIBOR) | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	2.25%
Wells Fargo Bank, National Association | Secured Debt | Line of Credit | Credit Agreement, Interest Rate Option Two | London Interbank Offered Rate (LIBOR) | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.50%
Wells Fargo Bank, National Association | Secured Debt | Line of Credit | Credit Agreement, Interest Rate Option Two | London Interbank Offered Rate (LIBOR) | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	1.25%
Wells Fargo Bank, National Association | Secured Debt | Line of Credit | Credit Agreement, Interest Rate Option Two | Federal Funds Rate
Debt Instrument [Line Items]
Basis spread on variable rate	0.50%
Wells Fargo Bank, National Association | Revolving Credit Facility
Debt Instrument [Line Items]
Proceeds from lines of credit		0
Repayment of debt and revolving credit facility		0
Carry amount of debt		34,500,000		34,500,000	34,500,000
Wells Fargo Bank, National Association | Revolving Credit Facility | Line of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 200,000,000
Debt instrument, term (in years)	5 years
Wells Fargo Bank, National Association | Revolving Credit Facility | Line of Credit | Minimum
Debt Instrument [Line Items]
Unused capacity, percentage	0.20%
Wells Fargo Bank, National Association | Revolving Credit Facility | Line of Credit | Maximum
Debt Instrument [Line Items]
Unused capacity, percentage	0.35%
Wells Fargo Bank, National Association | Term Loan Facility
Debt Instrument [Line Items]
Proceeds from lines of credit		0
Repayment of debt and revolving credit facility		2,500,000
Carry amount of debt		$ 180,000,000		$ 180,000,000	$ 182,500,000
Wells Fargo Bank, National Association | Term Loan Facility | Line of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 200,000,000					$ 315,000,000
Debt instrument, term (in years)	5 years
Principal periodic payment, percent, years one and two	5.00%
Principal periodic payment, percent, years three and four	10.00%
Principal periodic payment, percent, year five	15.00%
Wells Fargo Bank, National Association | Letter of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 10,000,000
Wells Fargo Bank, National Association | Letter of Credit | Line of Credit | Minimum
Debt Instrument [Line Items]
Commitment fee percentage	1.50%
Wells Fargo Bank, National Association | Letter of Credit | Line of Credit | Maximum
Debt Instrument [Line Items]
Commitment fee percentage	2.25%
Wells Fargo Bank, National Association | Bridge Loan
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 10,000,000

Debt - Components of Debt (Deta

Debt - Components of Debt (Details) - USD ($) $ in Thousands	3 Months Ended		27 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Dec. 31, 2017
Components of beginning debt balance [Abstract]
Long term debt, current portion, net of deferred issuance cost at beginning of period	$ 17,708		$ 17,708	$ 15,208
Long-term debt, net	190,490		190,490	194,917
Debt Borrowing, Repayment, Amortization during period [Abstract]
Repayment of debt and revolving credit facility	(2,500)	$ (40,000)
Amortization of deferred issuance cost	573	$ 397
Components of ending debt balance [Abstract]
Long-term debt, current portion, net	17,708		17,708	15,208
Long term debt, net of deferred issuance cost at end of period	190,490		190,490	194,917
Wells Fargo Bank, National Association
Components of beginning debt balance [Abstract]
Debt under credit facilities at beginning of period	217,000
Deferred issuance cost, net at beginning of period	(6,875)
Total Debt, net of deferred issuance cost at beginning of period	210,125
Long term debt, current portion, net of deferred issuance cost at beginning of period	17,708		17,708	15,208
Long-term debt, net	190,490		190,490	194,917
Debt Borrowing, Repayment, Amortization during period [Abstract]
Proceeds from lines of credit	0
Deferred issuance cost, gross	0
Increase in borrowings net of deferred issuance cost	0
Repayment of debt and revolving credit facility	(2,500)		(139,500)
Amortization of deferred issuance cost	573
Decrease in repayment/amortization net of deferred issuance cost	(1,927)
Components of ending debt balance [Abstract]
Debt under credit facilities at end of period	214,500		214,500
Deferred issuance cost, net at end of period	(6,302)		(6,302)
Total Debt, net of deferred issuance cost at end of period	208,198		208,198
Long-term debt, current portion, net	17,708		17,708	15,208
Long term debt, net of deferred issuance cost at end of period	190,490		190,490	$ 194,917
Wells Fargo Bank, National Association | Term Loan Facility
Components of beginning debt balance [Abstract]
Debt under credit facilities at beginning of period	182,500
Debt Borrowing, Repayment, Amortization during period [Abstract]
Proceeds from lines of credit	0
Repayment of debt and revolving credit facility	(2,500)
Components of ending debt balance [Abstract]
Debt under credit facilities at end of period	180,000		180,000
Wells Fargo Bank, National Association | Revolving Credit Facility
Components of beginning debt balance [Abstract]
Debt under credit facilities at beginning of period	34,500
Debt Borrowing, Repayment, Amortization during period [Abstract]
Proceeds from lines of credit	0
Repayment of debt and revolving credit facility	0
Components of ending debt balance [Abstract]
Debt under credit facilities at end of period	$ 34,500		$ 34,500

Deferred revenue (Details)

Deferred revenue (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Revenue Recognition [Abstract]
Short-term deferred revenue	$ 95,709	$ 78,774
Deferred service revenue, cost of sales, current		16,900	$ 15,700
Long-term deferred revenue	$ 8,806	$ 10,623

Commitments and Contingencies52

Commitments and Contingencies (Details) $ in Thousands	Mar. 31, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
Remaining nine months of 2018	$ 8,896
2,019	11,763
2,020	10,803
2,021	10,515
2,022	8,818
Thereafter	26,383
Total minimum future lease payments	77,178
Purchase obligation due within the next twelve months	$ 55,400

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Annual effective tax rate	18.00%	39.00%
Unrecognized tax benefits		$ 11.6	$ 10.7
Accrued interest and penalties		$ 1.5	$ 1.4

Employee Benefits and Share-B54

Employee Benefits and Share-Based Compensation - Shared-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 6,528	$ 5,511
Cost of product and service revenues
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	1,019	982
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	1,234	897
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 4,275	$ 3,632

Employee Benefits and Share-B55

Employee Benefits and Share-Based Compensation - Valuation of Share Based Awards, Table (Details)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	4 years 9 months 15 days	4 years 8 months 1 day
Expected volatility, %	32.20%	31.10%
Risk free interest rate, %	2.57%	1.89%
Estimated forfeiture rate %	6.90%	7.70%
Dividend yield, %	0.00%	0.00%
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield, %	0.00%	0.00%
Expected volatility, %, Min	25.80%	25.80%
Expected volatility, %, Max	33.80%	32.80%
Risk free interest rate, %, Min	0.70%	0.52%
Risk free interest rate, %, Max	2.25%	1.31%
Employee Stock Purchase Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	6 months	6 months
Employee Stock Purchase Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	2 years	2 years

Employee Benefits and Share-B56

Employee Benefits and Share-Based Compensation - Stock Option Activity (Details) - 2009 Plan - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Number of Shares
Outstanding at beginning of period (in shares)	3,323
Granted (in shares)	482
Exercised (in shares)	(87)
Expired (in shares)	(1)
Forfeited (in shares)	(43)
Outstanding at end of period (in shares)	3,674		3,323
Exercisable at end of period (in shares)	1,474
Vested and expected to vest at end of period (in shares)	3,456
Weighted Average Exercise Price
Outstanding beginning balance (in dollars per share)	$ 32.72
Granted (in dollars per share)	44.38
Exercised (in dollars per share)	22.50
Expired (in dollars per share)	24.09
Forfeited (in dollars per share)	37.14
Outstanding ending balance (in dollars per share)	34.45		$ 32.72
Exercisable at end of period (in dollars per share)	25.36
Vested and expected to vest at end of period (in dollars per share)	$ 33.94
Weighted-average remaining years, outstanding	7 years 3 months 11 days		7 years 7 months 13 days
Weighted-average remaining years, exercisable at end of period	5 years 4 months 6 days
Weighted-average remaining years, vested and expected to vest at at end of period	7 years 2 months 9 days
Aggregate Intrinsic Value
Aggregate intrinsic value, outstanding at end of period	$ 37,607		$ 53,953
Aggregate intrinsic value, exercisable at end of period	26,596
Aggregate intrinsic value, vested and expected to vest at end of period	$ 36,818
Employee Stock Option
Aggregate Intrinsic Value
Weighted-average fair value (in dollars per share)	$ 14.22	$ 10.86
Intrinsic value of options exercised	$ 2,000	$ 2,900
Unrecognized compensation cost of unvested stock options		$ 23,100
Weighted average period of compensation cost not yet recognized (in years)	3 years

Employee Benefits and Share-B57

Employee Benefits and Share-Based Compensation - Employee Stock Purchase Plan (ESPP) Activity (Details) - Nineteen Ninety Seven Employee Stock Purchase Plan - Employee Stock Purchase Plan - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchases under ESPP (in shares)	289	259
Exercised (in dollars per share)	$ 26.30	$ 25.51
Unrecognized compensation cost		$ 6.5
Weighted average period of compensation cost not yet recognized (in years)	1 year 4 months 21 days

Employee Benefits and Share-B58

Employee Benefits and Share-Based Compensation - Restricted Stock Activity (Details) - 2009 Plan - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Restricted Stock Units (RSUs)
Number of Shares
Outstanding at beginning of period (in shares)	501
Granted (in shares)	71
Vested (in shares)	(50)
Forfeited (in shares)	(14)
Outstanding and unvested at end of period (in shares)		508	501
Weighted-Average Grant Date Fair Value
Outstanding and unvested (in dollars per share)	$ 38.90
Granted (in dollars per share)	44.32	$ 36.57
Vested (in dollars per share)	33.70
Forfeited (in dollars per share)	$ 39.05
Outstanding and unvested (in dollars per share)		$ 40.16	$ 38.90
Weighted-average remaining years, outstanding and unvested	1 year 6 months		1 year 6 months
Aggregate Intrinsic Value
Outstanding and unvested at end of period		$ 22,041	$ 24,293
Unrecognized compensation cost		17,200
Weighted average period of compensation cost not yet recognized (in years)	2 years 9 months 22 days
Restricted Stock Awards
Number of Shares
Outstanding at beginning of period (in shares)	23
Granted (in shares)	0
Vested (in shares)	0
Forfeited (in shares)	0
Outstanding and unvested at end of period (in shares)	23		23
Weighted-Average Grant Date Fair Value
Outstanding and unvested (in dollars per share)	$ 41.07
Granted (in dollars per share)	0
Vested (in dollars per share)	0
Forfeited (in dollars per share)	0
Outstanding and unvested (in dollars per share)	$ 41.08		$ 41.07
Aggregate Intrinsic Value
Unrecognized compensation cost		$ 100
Weighted average period of compensation cost not yet recognized (in years)	1 month 21 days

Employee Benefits and Share-B59

Employee Benefits and Share-Based Compensation - Performance Based Restricted Stock Unit Activity (Details) - 2009 Plan - Performance Shares - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Number of Shares
Outstanding at beginning of period (in shares)	225
Granted (in shares)	110
Vested (in shares)	(32)
Canceled (in shares)	(1)
Outstanding and unvested at end of period (in shares)	302
Weighted-Average Grant Date Fair Value Per Share
Outstanding and unvested (in dollars per share)	$ 31.18
Granted (in dollars per share)	38.03	$ 32.37
Vested (in dollars per share)	32.37
Canceled (in dollars per share)	43.20
Outstanding and unvested (in dollars per share)	$ 33.51
Unrecognized compensation cost	$ 5.4
Weighted average period of compensation cost not yet recognized (in years)	1 year 6 months

Employee Benefits and Share-B60

Employee Benefits and Share-Based Compensation - Summary of Shares Reserved for Future Issuance Under Equity Incentive Plans (Details) shares in Thousands	Mar. 31, 2017shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	7,314
Nineteen Ninety Seven Employee Stock Purchase Plan | ESPP shares available for future issuance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	2,077
2009 Plan | Share options outstanding
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	3,674
2009 Plan | Non-vested restricted share awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	833
2009 Plan | Shares authorized for future issuance
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares reserved for future issuance	730

Employee Benefits and Share-B61

Employee Benefits and Share-Based Compensation - Stock Repurchase Program (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Aug. 02, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares acquired (in shares)	0	0
The 2016 Repurchase Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase, authorized amount			$ 50,000,000
2016 and 2014 Share Repurchase Programs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase, remaining authorized repurchase amount		$ 54,900,000

Equity Offerings (Details)

Equity Offerings (Details)	Nov. 03, 2017USD ($)
Distribution Agreement
Subsidiary, Sale of Stock [Line Items]
Maximum aggregate offering price	$ 125,000,000

Segment and Geographical Info63

Segment and Geographical Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)segment	Mar. 31, 2017USD ($)	Dec. 31, 2017USD ($)
Segment Reporting [Abstract]
Number of operating segments | segment	2
Number of reportable segments | segment	2
Segment Reporting Information [Line Items]
Revenues	$ 182,619	$ 148,553
Cost of revenues	100,164	86,362
Gross profit	82,455	62,191
Operating expenses	81,822	78,743
Income (loss) from operations	633	(16,552)
Property and equipment, net	48,290		$ 42,595
United States
Segment Reporting Information [Line Items]
Revenues	158,202	130,279
Property and equipment, net	40,116		34,899
Rest of world
Segment Reporting Information [Line Items]
Revenues	24,417	18,274
Property and equipment, net	8,174		$ 7,696
Automation and analytics
Segment Reporting Information [Line Items]
Revenues		122,170
Gross profit		53,409
Medication adherence
Segment Reporting Information [Line Items]
Revenues		26,383
Gross profit		8,782
Operating segments
Segment Reporting Information [Line Items]
Revenues	182,619	148,553
Cost of revenues	100,164	86,362
Gross profit	82,455	62,191
Operating expenses	58,589	59,258
Income (loss) from operations	23,866	2,933
Operating segments | Automation and analytics
Segment Reporting Information [Line Items]
Revenues	151,406	122,170
Cost of revenues	78,242	68,761
Gross profit	73,164	53,409
Operating expenses	48,390	48,062
Income (loss) from operations	24,774	5,347
Operating segments | Medication adherence
Segment Reporting Information [Line Items]
Revenues	31,213	26,383
Cost of revenues	21,922	17,601
Gross profit	9,291	8,782
Operating expenses	10,199	11,196
Income (loss) from operations	(908)	(2,414)
Corporate
Segment Reporting Information [Line Items]
Operating expenses	$ 23,233	$ 19,485

Restructuring Expenses (Details

Restructuring Expenses (Details) $ in Millions	Feb. 15, 2017Employee	Mar. 31, 2017USD ($)	Mar. 31, 2018USD ($)	Mar. 02, 2018USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring expected cost				$ 1.5
Number of positions eliminated | Employee	100
Employee severance
Restructuring Cost and Reserve [Line Items]
Restructuring expected cost		$ 3.8
Restructuring expenses paid		2.1
Facility-related cost
Restructuring Cost and Reserve [Line Items]
Facility-related costs incurred		0
Accrued severance and related expenses | Employee severance
Restructuring Cost and Reserve [Line Items]
Restructuring reserve, unpaid balance in accrued compensation		$ 1.7	$ 1.4

Subsequent Event (Details)

Subsequent Event (Details) $ in Millions	3 Months Ended
	Jun. 30, 2018USD ($)
Ateb | Subsequent Event
Subsequent Event [Line Items]
Settlement of certain contingencies	$ 2.5